HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OTC Switch Expert Panels Supported By AHA

This article was originally published in The Tan Sheet

Executive Summary

The American Heart Association supports establishing expert panels that would determine what additional research is needed before a decision on a potential switch candidate can be made. The association's comments refer specifically to statin drugs.

You may also be interested in...

Red Yeast Rice Safety Advantage Over Rx Statins Cited By UCLA Researcher

Differentiating the metabolic activity of red yeast rice from that of Rx statins could create a "widescale public health prevention" need for botanical supplements unencumbered by the toxicity and safety concerns associated with cholesterol-lowering drugs, according to a University of California at Los Angeles researcher.

Benecol, Take Control Marketing Highlight Approved CHD Health Claims

McNeil Consumer Healthcare's Benecol spread will soon be carrying labeling stating it can reduce the risk of coronary heart disease, the company said. The new labeling follows FDA's Sept. 8 approval of McNeil's health claim petition.

Mevacor Study Comparing Rx, OTC Use Is Among FDA Panel Suggestions

Merck should conduct a head-to-head comparison study of Mevacor use in prescription and over-the-counter settings, Endocrinologic & Metabolic Drugs Advisory Committee member William Tamborlane, MD, said during a review of Merck's OTC switch application for lovastatin 10 mg.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts